The Jordan Peterson nerve You may have first heard of the Vagus nerve from the infamous breathing coach turned self-help junkie Wim Hof. Hof has become an iconic figure…
Gavinchuk
Natty Filament Health is fresh off a $10 million CAD raise backed by Cannacord that closed yesterday, priced at $0.50 per share. Tomorrow they will make the shift to…
Atai is already a whale Although private, no shroom stock discussion is complete without mentioning Berlin-based Atai Life Sciences. The company has remained private since its inception in…
A different approach to MDD I’m big on companies having a unique approach to whatever they are doing. Many psychedelics companies are targetting depression but from a psychedelic-assisted therapy…
‘Growth hacking’ Early on in the shroom boom critics had one major pain point – legalization is too far away. I remember the stiffs at the Cannacord conference a…
Multiple pivots Mind Cure (MCUR.C) began as a mushroom nootropic deal that has since shifted to ibogaine production and the development digital platforms. The company has been able to…
In a groundbreaking story MindMed (MNMD.Q) announced today has been granted approval by the Swiss Ethics Committee to evaluate the acute effects of different doses of mescaline and the…
They seem to have been born that way. They are naturally incapable of grasping and developing a manner of living which demands rigorous honesty. Today Alcoholics Anonymous (AA) is…
Survivors of childhood trauma Everyone’s therapy journey is different. Some people can move past what they are dealing with purely through talk therapy. By understanding on a logical level…
Serotonin over psychedelics Bright Minds Biosciences (DRUG.C) isn’t banking on recreational psychedelics being relevant any time soon, they aren’t selling mushroom powder, and don’t own any ketamine clinics. Rather,…